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BACKGROUND: Fibromatosis comprises distinct clinical entities, including sporadic extra-abdominal fibromatosis, which have a high
tendency for recurrence, even after adequate resection. There are no known molecular biomarkers of local recurrence. We searched
for b-catenin mutations in a European multicentre series of fibromatosis tumours to relate b-catenin mutational status to disease
outcome.
METHODS: Direct sequencing of exon 3 b-catenin gene was performed for 155 frozen fibromatosis tissues from all topographies.
Correlation of outcome with mutation rate and type was performed on the extra-abdominal fibromatosis group (101 patients).
RESULTS: Mutations of b-catenin were detected in 83% of all cases. Among 101 extra-abdominal fibromatosis, similar mutation rates
(87%) were observed, namely T41A (39.5%), S45P (9%), S45F (36.5%), and deletion (2%). None of the clinico-pathological
parameters were found to be significantly associated with b-catenin mutational status. With a median follow-up of 62 months,
51 patients relapsed. Five-year recurrence-free survival was significantly worse in b-catenin-mutated tumours regardless of a specific
genotype, compared with wild-type tumours (49 vs 75%, respectively, P¼0.02).
CONCLUSION: A high frequency (87%) of b-catenin mutation hallmarks extra-abdominal fibromatosis from a large multicentric
retrospective study. Moreover, wild-type b-catenin seems to be an interesting prognostic marker that might be useful in the
therapeutic management of extra-abdominal fibromatosis.
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Fibromatoses are rare, locally invasive soft-tissue tumours
composed of spindle cells that display a wide spectrum of
aggressiveness. These star-shaped soft tissues, devoid of a capsule,
invade surrounding structures and have a high propensity for local
recurrence (Sobin and Wittekind, 2002).
Clinical forms of the disease depend on the tumour site:
abdominal fibromatosis (deep or desmoid), which occurs on the
abdominal wall of women in association with hormonal factors;
intra-abdominal fibromatosis, some forms of which are associated
with germ-like mutations of the adenomatous polyposis coli (APC)
gene-associated Gardner syndrome; and extra-abdominal fibro-
matosis, which occurs in the head and neck, trunk, and limbs.
Sporadic extra-abdominal fibromatosis has a high tendency for
local recurrence, even after apparently adequate resection. In
institutional retrospective studies, local failure rates at 5 years have
ranged from 25 to 60% (Bonvalot et al, 2008). This wide range
reflects the great variability of accrual, treatments, and follow-up
in this rare disease, which has not yet been investigated in a
randomised controlled study. Traditionally, patients undergo
standard surgery, with the primary goal always being to achieve
complete resection with negative margins, as indicated for
sarcomas. However, Bonvalot et al (2008) recently questioned
the need for systematically including surgery and other aggressive
treatments in the first-line treatment of primary extra-abdominal
desmoid tumours. In their study, tumour growth arrest occurred
in two-thirds of patients managed non-surgically. A larger, multi-
institutional study conducted recently also showed that a wait-and-
see approach avoided the need for aggressive surgery and
radiotherapy in the majority of patients with primary tumours
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cells and the host microenvironment, for example, could account
for highly diverse outcomes.
To date, no predictive criteria (clinical, histological, or
biological) that might help oncologists in the clinical management
of patients with extra-abdominal fibromatosis have been identi-
fied. From a biological point of view, desmoids and extra-
abdominal fibromatosis tumours typically harbour mutations of
APC and/or b-catenin genes (Alman et al, 1997; Tejpar et al,
1999). Adenomatous polyposis coli is known to regulate the
cytoplasmic level of b-catenin, which is involved in cell adhesion
and has a key role in the Wnt (Wingless) signalling pathway.
The phosphorylation of b-catenin on threonine 41 and serine 33,
37, and 45, encoded by exon 3 of the b-catenin gene, occurs
when b-catenin binds to APC and leads to protein degradation
through the ubiquitin–proteasome pathway (Orford et al, 1997;
Rubinfeld et al, 1997). Adenomatous polyposis coli mutations
give rise to b-catenin protein accumulation and induce Wnt
pathway activation. b-Catenin gene missense mutations, in turn,
lead to post-translational stabilisation of the protein and
translocation from the cytoplasm to the nucleus, where b-catenin
binds to the T-cell factor lymphoid enhancer family, resulting
in transcription transactivation (Morin et al, 1997). Such muta-
tions had only been described in small series of desmoid tumours
until very recently when Lazar et al (2008) reported a high
frequency of b-catenin mutations in the vast majority of
fibromatoses.
In this study, we analysed a large series of extra-abdominal
fibromatoses (with follow-up data spanning over 5 years) collected
through the connective tissue cancer network Conticanet in
France, Belgium, and Switzerland to evaluate whether b-catenin
mutational status might constitute a valuable biomarker for
recurrence that could improve the therapeutic management of
such disabling tumours.
MATERIALS AND METHODS
Tumour material of patients
All tumour samples were collected through CONTICANET and
stored in a centralised tumour data bank at the Bergonie ´ Institute
in Bordeaux, France, after obtaining approval from the appro-
priate ethics committees. This European fibromatosis tumour
database contained exhaustive clinical information and follow-up
data for over 5 years. From this tumour database, 187 eligible
fibromatosis tumour tissues collected between December 1987
and January 2007 were tested in this retrospective study. Most of
the patients with extra-abdominal fibromatosis had been surgi-
cally treated with curative intent. The tumour material comprised
tumour samples from biopsies or microbiopsies performed using
16- or 18-gauge needles. The tissues had been obtained after
surgery at diagnosis and snap-frozen in liquid nitrogen. Twenty-
three formalin-fixed, paraffin-embedded (FFPE) tumour samples
paired to frozen tumour samples were also obtained, as were
35-mm-thick tumour slices flanked by 4-mm sections from either
frozen or FFPE fibromatosis tumours for use as histolo-
gical controls (haematoxylin–eosin–saffron staining). The histo-
logical controls were analysed by pathologists specialised in soft-
tissue tumours (Ph T and JMC). Over 90% of the histological
features identified were typical of fibromatosis in all tumours
analysed.
b-Catenin gene sequencing
Following lysis of the 35mm tumour slices, nucleic acids were
obtained using Qiagen column separation according to the manu-
facturer’s instructions (Qiagen, Hilden, Germany). Available
DNA for sequencing was obtained in 155 desmoid-type
fibromatosis tumour biopsy specimens including all clinical forms
of the disease. DNA lymphocytes from 96 anonymous individuals
were used as non-mutated controls. The CTNNB1 mutations
located in exon 3 were analysed by direct DNA sequencing. The
genomic DNA was first amplified by polymerase chain reaction
(PCR) of over 35 cycles at an annealing temperature of 551C
(forward primers: 50-ATTTGATGGAGTTGGACATGGC-30 and
reverse: 50-CCAGCTACTTGTTCTTGAGTGAAGG-30) as previously
described (Delmas et al, 2007). All PCR amplimers were checked
using 1% agarose gel electrophoresis. Sequencing reactions were
performed using a BigDye terminator cycle sequencing kit
and analysed on a 48-capillary 3730 DNA Analyzer (Applied
Biosystems, Foster City, CA, USA). Exonic sequences were read
and aligned using SeqScapeR software (Applied Biosystems).
As reference for b-catenin gene, NM 00109822091 aligned on a
sequence of chromosome 3 (NCBI 36) was used.
Patient population and clinical data
The varying clinical forms of fibromatosis (sporadic tumours,
intra-abdominal tumours associated with hereditary syndrome,
and deep and extra-abdominal tumours) were all represented in
the Conticanet series of tumours used for this study. Of 155
fibromatosis tissues from all topologies available for DNA
sequencing, 101 extra-abdominal fibromatoses were used to
investigate the correlation between b-catenin mutational status
and clinical characteristics: age, sex, tumour size, tumour
location (head and neck, abdominal and thoracic walls and limbs),
therapy (including quality of surgical resection as assessed by
type of resection (R0, R1, or R2 according to the UICC-R
classification system)) (Lev et al, 2007), and outcome (for 101
patients treated with a curative intent). R0 resection was obtained
for 42 patients.
Statistical analysis
Survival times were calculated from the date of diagnosis to the
date of relapse (disease-free survival). Log-rank tests were used for
survival outcome analysis. Descriptive statistics were used to
correlate patient characteristics to the b-catenin genotype, and the
relationship between clinical characteristics and b-catenin muta-
tional status was analysed using logistic regression analysis.
RESULTS
High frequency of b-catenin gene mutation in frozen
tumour specimens
Of the 155 sequenced DNA from tumour samples obtained from
the Conticanet fibromatosis tumour database, 129 (83%) contained
a mutation of b-catenin exon 3. No mutations were detected in the
DNA extracted from lymphocytes of the 96 controls. All sequences
were controlled in an independent experiment. The rate of
mutation identified (83%) confirms and updates the findings of
a preliminary report by our group on the basis of 95 cases from
the same series (Domont et al, 2009).
b-Catenin missense mutations were essentially found at codons
41 and 45, identified as c.121 A4G or pThr-41-Ala (T41A),
c.133T4C or pSer45Pro (S45P), and c.134C4T or pSer45Phe
(S45F). The 41A and S45F mutations were relatively common,
occurring in 41% (64 out of 155) and 34% (53 out of 155) of cases,
whereas the S45P mutation occurred in just 6% (9 out of 155)
(Figure 1). In three cases (2%), we also detected a small in-frame
deletion of 3, 6, and 30 base pairs, which removed codon 36,
codons 33 and 34, and codons 45–54, respectively.
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sPotential diagnostic interest of mutation analysis on
formalin-fixed tissues
The clinical potential of the above results obtained from frozen
tumour tissues led us to test the feasibility of sequencing using
FFPE tissues, which are more readily available in daily practice. We
therefore compared sequencing results from the FFPE samples
paired to the frozen tumour specimens of the series. We observed
identical data in 20 out of 23 (87%) samples, with no false positives
and just three false negatives from FFPE tissues. Archival FFPE
tumour tissues might thus provide useful and easily obtainable
material for determining b-catenin mutational status in daily
practice.
Characteristics of patients with extra-abdominal
fibromatosis by b-catenin genotype
The European fibromatosis tumour database contained exhaustive
clinical information, with follow-up data for over 5 years, for 101
patients (36 men) with extra-abdominal fibromatosis that had been
surgically treated with curative intent. Fifty-seven patients had
been treated for primary fibromatosis (57%) and 40 for relapse
(40%) (Table 1). The b-catenin mutation rate detected in this
group (87% (88 out of 101)) was similar to that detected for the
whole series, as was the distribution of mutation types (T41A,
39.5% (40 out of 101), S45F, 36.5% (37 out of 101), and S45P, 9% (9
out of 101)) (Figure 1). We also found two deletions (2%). Table 1
shows patient characteristics according to b-catenin mutational
status. Most of the surgical margins were R0 (42%) or R1 (34%).
Few patients had received postoperative radiation therapy (18%)
or medical treatment (8%). With a median follow-up of 62 months
(range 3–452), 51 patients (51%) relapsed. b-Catenin mutational
status was not found to be significantly associated with sex, age,
tumour site, presentation (primary or relapse), or therapy. No
correlation could be established between surgical resection quality
and mutation rate.
Correlation of outcome with mutation rate and type
To test whether b-catenin mutational status correlated with clinical
outcome in patients with extra-abdominal fibromatosis, we
compared the frequency of disease-free survival (estimated
from the date of diagnosis to the date of relapse) in patients
with wild-type and b-catenin-mutated tumours. Among 51
relapses (51% of the cohort), 1 and 50 were from patients with
wild-type tumour and mutated tumour, respectively. Five-year
recurrence-free survival (Figure 2) was significantly shorter in all
b-catenin-mutated tumours (43%), compared with wild-type
tumours (75%) (P¼0.02). We then attempted to relate poor
outcome to a specific genotype but found no significant differences
for T41A, S45F, or S45P mutants, although the 45F mutation did
seem to show a weak trend of significance for poorer outcome.
Given the possible prognostic impact of surgical margin quality,
we analysed the b-catenin genotype in patients with R0
resection (n¼42) and found relapse to be significantly higher in
patients with mutated tumours (18 out of 33) than wild-type
tumours (0 out of 9) (P¼0.02), as shown in the Kaplan–Meier
graph (Figure 3).
DISCUSSION
As dysregulation of expression and mutation of b-catenin
hallmarks sporadic aggressive fibromatosis (Tejpar et al, 1999),
we searched for exon 3 b-catenin gene mutations in a large
European multicentre series of extra-abdominal fibromatosis
tumours. Indeed, mutations of exon 3 of b-catenin, which
harbours phosphorylable serine/threonine residues, induce stabi-
lisation of b-catenin and subsequent biological properties such as
proliferation and invasiveness.
Our study revealed a high frequency of b-catenin mutations in
fibromatosis tumours (n¼155), and in extra-abdominal forms in
particular (n¼101), results similar to that reported by another
study (Lazar et al, 2008) that included a similar-sized series of
fibromatosis tumours (n¼138). Remarkably, all mutations
clustered at Threonine 41 (T41A) and Serine 45 (S45F and S45P)
in all topographies, suggesting that these residues have crucial
functions in the b-catenin/Wnt signalling pathway required for the
maintenance of fibroblast/myofibroblast homoeostasis (Cheon
et al, 2002; Clevers, 2006; Polakis, 2007). Irrespective of the
molecular mechanism at work behind these two specific residues
(Xu et al, 2007), a high frequency of mutations (87%) hallmarks
c.134 C>T; p.S45F
WT ACA CCT TCT CTG AGT GGT
Mut ... ...
c.121 A>G; p.T41A
WT GGT GCC ACT ACC CCT
Mut
c.133 T>C; p.S45P
WT ACA GCT CCT TCT CTG AGT GGT
Mut ... ... ... ... ... ... C.. ... ... .T. ... ...
GCT
... ... ... G.. ... ... ...
GCT ACA
Figure 1 b-Catenin mutations detected in extra-abdominal fibromatosis tumours. Typical heterozygous missense mutations found in exon 3 b-catenin
gene at codons 41 (T41A) and 45 (S45F and S45P).
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sextra-abdominal fibromatosis at a molecular level. On studying a
series of 101 such tumours, we found that 5-year recurrence-free
survival was significantly worse in all mutated tumours (43%)
compared with wild-type tumours (75%) (P¼0.02). However, no
specific mutant genotypes (T41A, S45F, or S45P mutants) were
related to prognosis, although we did observe a weak trend for
S45F, but it was far from significant. Our results contrast with
those of a very recent American study proposing that patients with
fibromatosis harbouring an S45F mutation are at particular risk of
recurrence (Lazar et al, 2008). The discrepancy may reflect
differences in the clinical entities studied. Although our study
was restricted to extra-abdominal tumours, Lazar et al (2008) also
included deep abdominal tumours.
Evidence that b-catenin mutations influence the risk of relapse
is further strengthened by our analysis of patients with R0
resections, in which relapse-free survival was significantly
higher in wild-type than in mutated tumours. Hence, as
extra-abdominal fibromatosis relapse is clinically unpredictable,
its risk of occurrence could be evaluated using b-catenin
mutational status: a wild-type tumour, for example, would
predict good outcome, whereas a b-catenin mutation would
predict a potential risk of relapse. It is probably not the only
factor involved, however, as wild-type tumours represent 16%
of cases in our study, whereas indolent extra-abdominal fibro-
matosis represents roughly 50% of the patients according
to a recent multi-institutional European analysis (Fiore et al,
2009). Therefore, several mutated tumours harbouring stabilised
b-catenin do not relapse. Various mechanisms could explain
this paradox. First of all, it is possible that deregulation
of additional molecular actors of the canonical Wnt pathway –
from the receptor (with agonists and antagonists) to cyto-
plasmic effectors and finally to the target gene – may contribute
to the tumour phenotype. Second, alteration of the non-canonical
Wnt pathway and effectors must also be considered. Hence,
additional prospective studies are needed to find more discrimi-
nant markers.
Finally, from a practical point of view, the feasibility test
comparing sequences from frozen and FFPE tumour tissues
showed that b-catenin mutational status can be assessed using
either fresh or archival extra-abdominal tumour specimens in
Table 1 Characteristics of patients with extra-abdominal fibromatosis by
b-catenin genotype
CTNNB1 Total WT Mutated 41A 45F 45P del
characteristics nnn n n n
N 101 13 88 40 37 9 2
Age
Median, years 37 39.5 37.5 36.7 37 45.5 43
Range 0.1–77 0.5–66 0.1–77 10–73 0.1–77 14–65 19–68
Sex
Male 36 4 32 14 15 3 —
Female 65 9 56 26 22 6 2
Presentation
Primary 57 12 45 16 20 8 1
Relapse 40 1 39 22 15 11
NA 4 — 4 2 2 — —
Tumour site
Head/Neck 8 1 7 2 5 — —
Trunk 54 5 49 20 19 8 2
Limb 37 7 30 17 12 1 —
NA 2 — 2 1 1 — —
Tumour size, mm
Median, mm 80 40 80 80 85 75 40
Range 10–300 15–120 10–300 21–300 25–200 25–190 10–70
Therapy
Surgery 101 13 88 40 37 9 2
Radiation therapy 18 1 17 7 8 1 1
Medical therapy 8 1 7 3 4 — —
Surgical margin
RO 42 9 33 14 13 5 1
R1 33 3 30 15 12 3 —
R2 8 — 8 1 5 1 1
NA 18 1 17 10 7 — —
Outcome
Relapse 51 1 50 22 23 4 1
Patient clinical data and b-catenin genotype tumour data from the series of
extra-abdominal fibromatosis tumours. WT, wild b-catenin gene (exon 3) del,
deletion in exon 3; 41A, 45F, 45P, mutated residues; n, number of patients; NA, not
available; mm, millimiter; R0, R1, and R2, quality of surgical margins according to the
UICC-R classification system.
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Figure 2 Kaplan–Meier graph of relapse-free rate–time as a function of
a mutation event. Plots of time from time of first surgery to remove tumour
(primary or relapse) of extra-abdominal fibromatosis (EAF) to the first
recurrence event according to Kaplan–Meier for the entire cohort
(n¼101). Plot of time from tumour surgery (primary or relapse) to
recurrence event. Analysis reveals that the mutated genotype, irrespective
of the b-catenin mutation (T41A, S45F, or S45P), is a significant predictor of
relapse (P¼0.02).
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Figure 3 Kaplan–Meier representation of relapse-free rate–time as a
function of a mutation event for patients operated for extra-abdominal
fibromatosis (EAF) with RO resection (n¼42). Plot of time from tumour
surgery (primary or relapse) to recurrence event. Multivariate analysis
reveals that the b-catenin-mutated genotype, irrespective of the mutation
(T41A, S45F, or S45P), is a significant predictor of relapse (P¼0.02).
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saccordance with the tumour collection system used in each
pathology laboratory. This simple yet efficient molecular test
might prove to be a very interesting complementary diagnostic
tool to regular histological examination in extra-abdominal
fibromatosis. Indeed, in cases in which there is insufficient
tumour material for histological analysis, b-catenin sequencing
could be performed, as it requires just a few ng of gDNA. The test
could also be helpful to resolve puzzling cases in which the
histological interpretation of primary tumour tissue obtained by
fine-needle aspiration is complicated.
A final application would be to use molecular tumour findings
to individualise the choice of management protocols. This
application of personalised medicine in patients with extra-
abdominal fibromatosis could help to identify the right treatment
at the right time for optimal outcome.
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